Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by Ricky55on Apr 12, 2013 3:03pm
141 Views
Post# 21248303

RE: RE: Simple math..correction

RE: RE: Simple math..correction

The way i see it ,is this way:

The cost production for each onces of gold is around $700.00 and the sale price could be approx.$1350.00 ---$1400.00.Therfore,according to me:3 millions onces multiply by $1400 less $700.00 equal a net profit of $2.1 billions divided by the ammount of years or the lifetime of the project.

Let say ,20 years;  equal $105 millions a years including big money for the people who works there as well for the direction.I would say $1.00 and+  a share just for one project.Many others things going on for Niogold.If the lifetime of the mine is 10 years,share price value climb at $2,00 a share for that specific project.

Someone who buy now is a sure winner in a couple of years.Be patient and keep your shares at that level.

 

<< Previous
Bullboard Posts
Next >>